Sustainable Healthcenter Implementation PrEP Pilot Study (SHIPP)

Centers for Disease Control and Prevention (CDC)

Status: Completed

Conditions: HIV Preexposure Prophylaxis; HIV Chemoprophylaxis

Treatments: Drug: coformulated TDF/FTC

Study type: Observational

Funder types: Other; Other U.S. Federal agency; Industry

Identifiers

NCT02074891

CDC-NCHHSTP-6511

Details and patient eligibility

About

A health services implementation pilot study, conducted with an observational cohort of HIV-uninfected persons including men who have sex with men, heterosexual women and men, and injection drug users receiving daily oral antiretroviral preexposure prophylaxis (PrEP) at four federally qualified health centers that provide sexual health and primary care services to communities with high HIV incidence/prevalence.

Enrollment: 1,420 patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• adult
• documented without HIV infection (acute or established)
• report sexual behaviors that indicate substantial risk of HIV acquisition
• report injection-related behaviors that indicate substantial risk of HIV acquisition

Exclusion criteria

• <18 years of age
• documented HIV infection (acute or established)

Trial design

1,420 participants in 1 patient group

Persons prescribed PrEP

Description:

adults prescribed daily oral antiretroviral preexposure prophylaxis (PrEP) with the coformulated TDF/FTC to reduce HIV acquisition.

Treatment:

Drug: coformulated TDF/FTC